Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$227K Sell
646
-120
-16% -$42.8K 0.02% 262
2025
Q4
$251K Hold
766
0.02% 238
2025
Q3
$216K Hold
766
0.02% 280
2025
Q2
$214K Hold
766
0.02% 254
2025
Q1
$239K Sell
766
-35
-4% -$10.3K 0.02% 236
2024
Q4
$209K Hold
801
0.02% 247
2024
Q3
$258K Hold
801
0.02% 222
2024
Q2
$250K Hold
801
0.02% 218
2024
Q1
$228K Hold
801
0.02% 238
2023
Q4
$231K Hold
801
0.03% 211
2023
Q3
$215K Buy
+801
New +$200K 0.03% 206

Other funds holding AMGN

Cardiff Park Advisors's AMGN Position: Q1 2026 in Review

Cardiff Park Advisors reduced its Amgen (AMGN) stake by 16% in Q1 2026, selling an estimated $42.8K and leaving 646 shares worth $227K. The position accounts for 0.02% of the portfolio, ranked #262.

Cardiff Park Advisors first reported a position in AMGN in Q3 2023 and has held it in 11 quarters since. The position peaked at $258K in Q3 2024. 3,128 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Cardiff Park Advisors held 646 shares of Amgen worth $227K as of Q1 2026.
  • Cardiff Park Advisors sold 120 Amgen shares in Q1 2026, an estimated $42.8K.
  • Amgen made up 0.02% of Cardiff Park Advisors's portfolio in Q1 2026, its #262 holding.
  • Cardiff Park Advisors first reported a position in Amgen in Q3 2023 and has held it in 11 quarters since.
  • Cardiff Park Advisors's Amgen position peaked at $258K in Q3 2024.
  • 3,128 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Cardiff Park Advisors's 13F filing for Q1 2026, filed 15 May 2026.